Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Terminated Phase 1 Interventional

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

NCT05956509
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
ABBV-950, BOTOX, Placebo for ABBV-950
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Carlsbad, California • Downey, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 23, 2026, 8:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ambulatory Medication Reconciliation Following Hospital Discharge

NCT00740675
View directory record Official record
Conditions
Medication Administered in Error, Adverse Drug Events
Interventions
Outpatient Medication Reconciliation
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
912 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections

NCT04439799
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone Cypionate 200 Mg/ML, Intranasal Testosterone
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Not applicable Interventional

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

NCT00748267
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Nausea and Vomiting, Pain
Interventions
questionnaire administration, hypnotherapy, therapeutic conventional surgery
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

NCT05771428
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-552, Placebo for ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial Comparison of Ototoxicity Monitoring Programs

NCT02099786
View directory record Official record
Conditions
Cisplatin Ototoxicity, Hearing Loss
Interventions
COMP-VA, Standard of care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 23, 2026, 8:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

NCT04777357
View directory record Official record
Conditions
Depression, Bipolar I Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
10 Years to 17 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
69
States / cities
Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Phase 1 Interventional

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

NCT00039481
View directory record Official record
Conditions
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, filgrastim, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 23, 2026, 8:30 AM EDT
Completed No phase listed Observational

Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting

NCT05091931
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Not listed
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Enrollment
3,308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 23, 2026, 8:30 AM EDT
Recruiting Phase 1 Interventional

IL-17 Blockade to Decrease irAEs (REPLAY)

NCT07237594
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Secukinumab Injection
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 8:30 AM EDT
Recruiting No phase listed Observational

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT07335341
View directory record Official record
Conditions
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions
Liberant Thrombectomy System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Naples, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 8:30 AM EDT
Active, not recruiting Not applicable Interventional

Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors

NCT01049230
View directory record Official record
Conditions
Germ Cell Tumor, Central Nervous System Germ Cell Tumor
Interventions
Proton Beam radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 25 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 8:30 AM EDT
Completed No phase listed Observational

Capturing Parkinson's Disease Medication Side Effects During Daily Activities

NCT01429207
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Not listed
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Not applicable Interventional

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies

NCT05786014
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
Interventions
High Intensity Interval Exercise, Moderate Intensity Walking
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 23, 2026, 8:30 AM EDT
Recruiting No phase listed Observational

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

NCT04262830
View directory record Official record
Conditions
Cardiotoxicity, Pediatric Cancer, Heart Failure
Interventions
Cardiac magnetic resonance imaging (MRI), Accelerometer physical activity monitoring
Diagnostic Test · Other
Lead sponsor
Hari Narayan
Other
Eligibility
13 Years to 39 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Side Effects of Atropine (SEA) Study

NCT03593044
View directory record Official record
Conditions
Myopia
Interventions
0.01% concentration atropine drops
Drug
Lead sponsor
Jeffrey J. Walline, OD PhD
Other
Eligibility
21 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 23, 2026, 8:30 AM EDT
Terminated Phase 3 Interventional Results available

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

NCT00305643
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pain
Interventions
Capecitabine, Celecoxib, Radiation Therapy, Placebo
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Not applicable Interventional

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 23, 2026, 8:30 AM EDT
Enrolling by invitation Not applicable Interventional

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT07499128
View directory record Official record
Conditions
Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions
TempTraq, VitalTraq
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 8:30 AM EDT
Completed Not applicable Interventional

Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy

NCT02796365
View directory record Official record
Conditions
Doxorubicin Induced Cardiomyopathy, Breast Cancer, Gastric Cancer, Leukemia
Interventions
Exercise
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 23, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of an Informed Consent Statement Which Communicates the Risk of Adverse Events Associated With Dry Needling

NCT05560100
View directory record Official record
Conditions
Dry Needling
Interventions
Nominal Group Technique - 2 to 3 hour virtual meeting
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 8:30 AM EDT
Terminated Phase 1 Interventional

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

NCT00003926
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 23, 2026, 8:30 AM EDT